Mendus
Courtagefri handel på Nordnet till sista juni 2027! Har du inget konto på Nordnet så är det verkligen läge att skaffa ett. Just nu får nya kunder courtagefri handel till sista juni 2027. Läs mer om erbjudandet och skapa ditt konto här Invitation to presentation of Mendus' second quarter 2026 financial report and business update
Mendus AB (“Mendus” publ; IMMU.ST) will publish its financial report for the second quarter 2026 on Thursday, August 20, at 08.00 CEST. The company will host a live presentation and business update on the same day at 14.00 CEST. The presentation will be held in English and includes a Q&A session.
Date and time: August 20 at 14.00 CEST
If you wish to participate via webcast please register using the link below. Via the webcast you are able to ask written questions.
https://portals.qbrick.com/520c8ac4
If you wish to participate via teleconference please register using the link below. After registration you will be provided phone numbers and a conference ID to access the conference. You can ask questions verbally via the teleconference.
https://event-registration.qbrick.com/AccDlMhN1SbO0mSeNwyp64iGw/019ff551-6595-7984-861c-72e68843e0a9/qbrick-meet-e6b334ca-c4ba-4f2b-bf86-7e8b69bd623b
For more information, please contact:
Erik Manting
Chief Executive Officer
E-mail: ir@mendus.com
About Mendus AB (publ)
Mendus is a clinical-stage biopharmaceutical company dedicated to transforming immunotherapy for myeloid malignancies. Based in Sweden and the Netherlands, Mendus is publicly traded on the Nasdaq Stockholm under the ticker IMMU.ST.
https://www.mendus.com/
| Datum | 2026-08-13, kl 08:00 |
| Källa | MFN |